Please login to the form below

Not currently logged in
Email:
Password:

Janssen

This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

Imbruvica gains expanded use in Europe

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US. AbbVie and Janssen’s Imbruvica (ibrutinib) has received approval from the European Commission (EC) for two expanded variations to broaden the use of the ... Despite this, AZ is looking to continue to

Latest news

More from news
Approximately 127 fully matching, plus 364 partially matching documents found.

Latest Intelligence

  • The first, my last, my everything The first, my last, my everything

    It’s a subtle but important nuance. It’s a similar story elsewhere, with companies like Roche, Janssen and MSD ‘partnering with patients’ to understand their needs and identify opportunities for

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Katrin Haeverans, EPAD LCS and POC platform support, Janssen said: “EPAD has been built to facilitate proof-of-concept trials. ... Sir Simon Lovestone. After 18 years in old age psychiatry and dementia research in academia, Sir Simon Lovestone joined

  • Deal Watch October 2018

    Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on.

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica.

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    Gilead’s HIV work continues apace as does that of rivals GSK, Sanofi, Janssen and others in a global HIV drug market expected to reach a value of $26, 458bn in

More from intelligence
Approximately 5 fully matching, plus 47 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics